Previous 10 | Next 10 |
home / stock / vphif / vphif news
VALEO PHARMA REPORTS RECORD QUARTERLY AND ANNUAL REVENUES FOR THE FOURTH QUARTER AND THE FISCAL YEAR 2022 Canada NewsWire Record quarterly revenues of $12.7 million in Q4-22, up 274% over Q4-21 Record revenues in 2022 of $27.7 million , up 105% over 2021 ...
(NewsDirect) Valeo Pharma chief executive Steve Saviuk joined Steve Darling from Proactive to share news the company has been told by Health Canada they have accepted for review Veru’s New Drug Submission (NDS-CV) for sabizabulin for COVID-19. Saviuk told Proactive Sabizabulin is a...
VALEO PHARMA ANNOUNCES FILING OF A NEW DRUG SUBMISSION-COVID 19 WITH HEALTH CANADA FOR SABIZABULIN FOR THE TREATMENT OF HOSPITALIZED COVID-19 PATIENTS Canada NewsWire In the final analysis of the Phase 3 cinical study conducted by Veru Inc., sabizabulin showed a 51.6% reduct...
VALEO PHARMA TO HOST FOURTH QUARTER AND YEAR-END 2022 RESULTS CONFERENCE CALL / WEBCAST Canada NewsWire MONTREAL , Jan. 25, 2023 /CNW Telbec/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmace...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Having gambled in under-the-radar penny stocks myself, I can tell you firsthand, the outcome hasn’t always been great. There are a lot of risks involved, so tread lightly. Many experts will advise you to steer clear o...
VALEO PHARMA ANNOUNCES SENIOR MANAGEMENT CHANGE Canada NewsWire Valeo's President and Chief Operating Officer steps down and will continue as special advisor and member of the Board of Directors MONTREAL , Nov. 21, 2022 /CNW Telbec/ - Vale...
Canadian pharmaceutical company Valeo Pharma ( OTCQB:VPHIF ) ( TSX: VPH:CA ) raised its Q4 revenue guidance to a range of $12.5M - $13.0M, up 14% to 18% over the previously-issued guidance of $11M. The consensus stands at $11.31M. The company also raised its FY...
VALEO PHARMA RAISES Q4 AND FULL YEAR 2022 REVENUE GUIDANCE Canada NewsWire Q4-2022 revenue guidance raised to a record $12.5M - $13.0M Fiscal 2022 revenue guidance increased to a record $27.5M - $28.0M MONTREAL , Nov. 15, 2...
Valeo Pharma ( OTCQB:VPHIF ) said it signed a commercial services agreement with Veru for COVID-19 drug sabizabulin in Canada. Sabizabulin is an antiviral and anti-inflammatory drug being developed to treat patients hospitalized with moderate-severe COVID-19 who ...
VALEO PHARMA ENTERS INTO CANADIAN COMMERCIAL SERVICES AGREEMENT WITH VERU FOR SABIZABULIN IN HOSPITALIZED ADULT PATIENTS WITH COVID-19 AT HIGH RISK FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) Canada NewsWire In a Phase 3 cinical study interim analysis, sabizabulin...
News, Short Squeeze, Breakout and More Instantly...
VALEO PHARMA ANNOUNCES SENIOR EXECUTIVE APPOINTMENT AND BOARD OF DIRECTORS CHANGE Canada NewsWire MONTREAL , June 18, 2024 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical compan...
(NewsDirect) Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to discuss the company's financial results for the second quarter, which saw record-breaking revenue for the period. The company reported revenues of $14.1 million for Q2, an increase from the $13.6 million rec...
VALEO PHARMA ANNOUNCES RESTRUCTURING OF COMMERCIAL FIELD OPERATIONS TO SUPPORT PATH TO PROFITABILITY Canada NewsWire Changes to respiratory business unit to generate more than $5 million in annual savings Follows previously announced cost saving measures exce...